Skip to main content
. 2019 Oct 18;11(10):964. doi: 10.3390/v11100964

Table 1.

The half-maximal cytotoxic concentration (CC50), the half-maximal effective concentration 1 (EC50-1) calculated using the CTG or CTxG assays, EC50-2 calculated using reporter protein expression, and the minimal selectivity indexes (SIs = CC50/EC50) for selected broad-spectrum antivirals. The measurements were repeated three times.

Compound Virus Cell Line Time (h) CC50 (mM) EC50-1 (mM) EC50-2 (mM) SI
Obatoclax HSV-2 RPE 72 1.23 ± 0.02 0.10 ± 0.02 12
Emetine HSV-2 RPE 72 1.12 ± 0.07 0.03 ± 0.01 37
Niclosamide HSV-2 RPE 72 1.31 ± 0.02 0.43 ± 0.04 3
Ganciclovir HSV-2 RPE 72 >30 0.04±0.01 >750
Obatoclax EV1 RPE 48 3.21 ± 0.04 0.12 ± 0.01 25
Emetine EV1 RPE 48 >30 0.12 ± 0.04 >300
Homoharringtonine EV1 RPE 48 >30 0.14 ± 0.03 >300
Brequinar HIV-1 TZM-bl 24 >30 0.04 ± 0.01 >750
Suramin HIV-1 TZM-bl 24 >30 0.08 ± 0.03 >375
Obatoclax RVFV RPE 24 >30 0.04 ± 0.01 0.32 ± 0.09 >100
Emetine RVFV RPE 24 >30 0.10 ± 0.02 0.43 ± 0.10 >75
Obatoclax HMPV RPE 96 0.60 ± 0.04 0.12 ± 0.02 6
Emetine HMPV RPE 96 1 0.14 ± 0.05 10
Obatoclax FLUAV RPE 24 3.11 ± 0.09 0.04 ± 0.01 0.10 ± 0.01 31
Emetine FLUAV RPE 24 >30 0.13 ± 0.05 0.12 ± 0.03 >300